Just days after Bahija Jallal announced her decision to leave her post at the top of AstraZeneca’s big biologics subsidiary MedImmune and take the helm at Immunocore, the pharma giant is shaking up its R&D leadership and bringing in a controversial new head of oncology R&D--José Baselga.
.
https://endpts.com/astrazeneca-names-controversial-cancer-scientist-jose-baselga-to-a-top-rd-post-in-major-shakeup/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.